ADC Therapeutics (ADCT) Stock Forecast & Price Target

ADC Therapeutics is viewed positively because Zynlonta is already commercially approved, which lowers regulatory risk and provides tangible cash flow from an FDA-marketed product in relapsed or refractory large B-cell lymphoma. Its clinical efficacy supports continued physician adoption and creates upside from broader use across indications, including potential expansion into additional indolent lymphomas and earlier lines of treatment. The capital raise in 4Q25 is expected to extend cash runway until 2028, giving the company sufficient funding to pursue its expansion opportunity while commercial strength in the United States and EMEA supports revenue momentum.

ADC Therapeutics is facing a weakened fundamental outlook because LOTIS-5 delivered only a modest PFS benefit (HR 0.73) without an OS advantage (HR 0.96), while Grade 5 TEAEs were elevated, prompting FDA “substantial concerns” about benefit-risk and verification of clinical benefit. Its core commercial asset, ZYNLONTA, generated just $18.6M in 2Q net sales, and the company now expects a slower revenue ramp in 2027 with lower approval probability in 2L DLBCL. Although it ended 2Q with $219M in cash and a runway at least into 2028, regulatory uncertainty, a crowded lymphoma market, and limited differentiation versus other therapies create significant pressure on future growth and valuation.